Amedeo Smart

Free Medical Literature Service

 

Amedeo

Breast Cancer
  Free Subscription

Articles published in
Histopathology
    December 2025
  1. KAIN ZE, Baez-Navarro X, Linn SC, van Deurzen CHM, et al
    Decision-making in breast pathology reporting: the effect of clinical relevant thresholds.
    Histopathology. 2025;87:951-955.
    >> Share

  2. SUN M, Fu L, Ren H, Wang J, et al
    Two similar but distinct types of breast acinar cell carcinoma: evidence from histological, immunohistochemical and molecular features.
    Histopathology. 2025;87:904-914.
    >> Share

  3. STA INES FM, Eadara A, Quddus MR, Sung CJ, et al
    Re-appraisal of mucocele-like lesion of the breast with atypia: study of 34 cases with focus on impact of type and extent of atypia on upgrade.
    Histopathology. 2025;87:943-950.
    >> Share

    September 2025
  4. MAKHLOUF S, Almalki N, Sheha A, Atallah NM, et al
    Outcome prediction of oestrogen receptor-positive breast cancer based on a panel of oestrogen receptor-regulated genes.
    Histopathology. 2025 Sep 12. doi: 10.1111/his.15557.
    >> Share

    August 2025
  5. SALISBURY T, Rendi M, Bhalli R, Bean GR, et al
    DCIS-like invasive carcinoma of the breast with tumour-associated microvasculature mimicking myoepithelium: a diagnostic pitfall.
    Histopathology. 2025;87:246-257.
    >> Share

  6. HAN R, Hashmi AA, Wen HY, Murray M, et al
    Clinicopathological features of microinvasive lobular carcinoma.
    Histopathology. 2025;87:235-245.
    >> Share

  7. TAN PH, Ellis IO, Allison KH, Badve SS, et al
    Malignant phyllodes tumours of the breast: the case for revising WHO's 'full house' diagnostic criteria.
    Histopathology. 2025;87:169-182.
    >> Share

    July 2025
  8. LEE AHS, Rakha EA, Hodi Z, Abbas A, et al
    Retesting of oestrogen receptor, progesterone receptor and HER2 status of invasive carcinoma of the breast after neoadjuvant chemotherapy.
    Histopathology. 2025;87:58-67.
    >> Share

    June 2025
  9. LAOKULRATH N, Nasir NDM, Gudi M, Tan PH, et al
    Diagnostic accuracy and challenges of intraoperative frozen section evaluation for axillary sentinel lymph node biopsy and breast margins.
    Histopathology. 2025;86:1121-1136.
    >> Share

  10. AL-REFAI R, Ali A, Roychoudhury S, Bendari A, et al
    Male breast atypical ductal hyperplasia (ADH): clinicopathological insights from a rare cohort.
    Histopathology. 2025;86:1137-1146.
    >> Share

    May 2025
  11. SOKOLOVA A, Joshi V, Chittoory H, Walsh M, et al
    ROS1 immunohistochemistry as a potential predictive biomarker for ROS1-targeted therapy in breast cancer: impact of antibody clone selection.
    Histopathology. 2025 May 13. doi: 10.1111/his.15465.
    >> Share

  12. EL SHEIKH S, Mansour MA, Provenzano E, Shaaban A, et al
    Diagnostic interobserver variability of atypia assessment in columnar cell lesions among a group of expert breast pathologists in the United Kingdom and the Republic of Ireland, on behalf of the UK national coordinating committee for breast pathology.
    Histopathology. 2025;86:953-966.
    >> Share

  13. HONG R, Wang H, Lin Y, Yin X, et al
    The clinicopathological and molecular features of primary high-grade neuroendocrine tumour in the breast.
    Histopathology. 2025;86:900-915.
    >> Share

    April 2025
  14. BOYRAZ B, Robinson B, Lindeman N, Hoda SA, et al
    Subareolar sclerosing ductal hyperplasia shows PI3K pathway alterations.
    Histopathology. 2025;86:824-827.
    >> Share

  15. KHEDR M, Gandhi S, Roy AM, Alharbi M, et al
    Breast biomarkers evolution between primary and distant metastasis: incidence and significance.
    Histopathology. 2025;86:793-804.
    >> Share

  16. KATAYAMA A, Makhlouf S, Toss MS, Oyama T, et al
    Nuclear morphological characterisation of lobular carcinoma variants: a morphometric study.
    Histopathology. 2025;86:813-823.
    >> Share

  17. KRINGS G, Shamir ER, Lae M, Bean GR, et al
    Serous-like breast carcinomas: immunophenotypic, genetic, and clinicopathologic characterization of a morphologically distinct group of tumours.
    Histopathology. 2025;86:779-792.
    >> Share

  18. YANG E, Fineberg S, Mohamed A, Brogi E, et al
    Variability in the diagnosis and reporting of metaplastic breast carcinoma: results of an international survey.
    Histopathology. 2025;86:742-749.
    >> Share

    March 2025
  19. KIM M, Lee M, Lee A, Choi BO, et al
    Correlating p53 immunostaining patterns with somatic TP53 mutation and functional properties of mutant p53 in triple-negative breast cancer.
    Histopathology. 2025 Mar 31. doi: 10.1111/his.15453.
    >> Share

  20. CHAN R, Leung H, Li J, Poon I, et al
    Evaluation of breast-specific marker expression in metastatic breast cancers: Correlation with subtype switch.
    Histopathology. 2025;86:536-546.
    >> Share

  21. RAKHA EA, Quinn C
    Controversies regarding encapsulated papillary carcinoma of the breast: an approach to evaluation and categorisation.
    Histopathology. 2025;86:497-513.
    >> Share

    February 2025
  22. AI D, Arrey EN, Postlewait LM, Gao Y, et al
    The prevalence and clinical significance of residual occult breast cancer after neoadjuvant chemotherapy: reassessing surgical pathology in cases initially described as pathological complete response.
    Histopathology. 2025 Feb 4. doi: 10.1111/his.15417.
    >> Share

  23. YANG E, D'Alfonso TM, Morrow M, Brogi E, et al
    Discordance of human epidermal growth factor receptor 2-low status between breast primary and distant metastases with clinical-pathological correlation.
    Histopathology. 2025;86:441-449.
    >> Share

  24. TAHA SR, Boulos F
    E-cadherin staining in the diagnosis of lobular versus ductal neoplasms of the breast: the emperor has no clothes.
    Histopathology. 2025;86:327-340.
    >> Share

    January 2025
  25. ASHI A, Awaji AA, Bond J, Johnson CA, et al
    Threonine and tyrosine kinase (TTK) mRNA and protein expression in breast cancer; prognostic significance in the neoadjuvant setting.
    Histopathology. 2025 Jan 7. doi: 10.1111/his.15399.
    >> Share

  26. LEE AHS, Hodi Z, Abbas A, Ellis IO, et al
    HER2-positive grade 1 invasive carcinomas of the breast.
    Histopathology. 2025;86:278-284.
    >> Share

    December 2024
  27. WANG Y, Liu L, Graff SL, Cheng L, et al
    Recent advancements in biomarkers and molecular diagnostics in hormonal receptor-positive breast cancer.
    Histopathology. 2024 Dec 17. doi: 10.1111/his.15395.
    >> Share

  28. ONAGI H, Horimoto Y, Okano S, Sasa K, et al
    Clinicopathological characteristics of Japanese patients with breast cancer and MET exon 14 skipping alterations.
    Histopathology. 2024 Dec 4. doi: 10.1111/his.15382.
    >> Share

  29. HEMPENIUS MA, Eenkhoorn MA, Hoeg H, Dabbs DJ, et al
    Quantitative comparison of immunohistochemical HER2-low detection in an interlaboratory study.
    Histopathology. 2024;85:920-928.
    >> Share

    October 2024
  30. MATSUMOTO H, Miyata R, Tsuruta Y, Nakada N, et al
    Ki-67 evaluation using deep-learning model-assisted digital image analysis in breast cancer.
    Histopathology. 2024 Oct 31. doi: 10.1111/his.15356.
    >> Share

  31. WANG Y, Liu L, Graff SL, Cheng L, et al
    Locoregional event or dyssynchronous distant metastasis: clinicopathological and molecular analysis of contralateral axillary lymph node metastasis in breast cancer patients.
    Histopathology. 2024 Oct 22. doi: 10.1111/his.15345.
    >> Share

    September 2024
  32. WONG CJW, Md Nasir ND, Koh VCY, Campbell F, et al
    Mapping the cited evidence of ductal carcinoma in situ from the 5th edition of the World Health Organisation classification of tumours of the breast.
    Histopathology. 2024;85:510-520.
    >> Share

  33. BATRA H, Bose PSC, Ding Y, Dai A, et al
    MYB expression by immunohistochemistry is highly specific and sensitive for detection of solid variant of adenoid cystic carcinoma of the breast among all triple-negative breast cancers.
    Histopathology. 2024;85:503-509.
    >> Share

  34. TURASHVILI G
    Nonneoplastic and neoplastic sclerosing lesions of the breast.
    Histopathology. 2024;85:383-396.
    >> Share

  35. GRABENSTETTER A, Brennan SB, Jochelson MS, Brogi E, et al
    Radial sclerosing lesions found on core needle biopsy: excision can be safely avoided.
    Histopathology. 2024;85:397-404.
    >> Share

  36. ELLIS I, Webster F, Allison KH, Dang C, et al
    Dataset for reporting of the invasive carcinoma of the breast: recommendations from the International Collaboration on Cancer Reporting (ICCR).
    Histopathology. 2024;85:418-436.
    >> Share

    August 2024
  37. ZWAGER MC, Yu S, Buikema HJ, de Bock GH, et al
    Advancing Ki67 hotspot detection in breast cancer: a comparative analysis of automated digital image analysis algorithms.
    Histopathology. 2024 Aug 5. doi: 10.1111/his.15294.
    >> Share

    July 2024
  38. BANNIER PA, Broeckx G, Herpin L, Dubois R, et al
    Development of a deep-learning model tailored for HER2 detection in breast cancer to aid pathologists in interpreting HER2-low cases.
    Histopathology. 2024 Jul 14. doi: 10.1111/his.15274.
    >> Share

  39. TOZBIKIAN G, Bui MM, Hicks DG, Jaffer S, et al
    Best practices for achieving consensus in HER2-low expression in breast cancer: current perspectives from practising pathologists.
    Histopathology. 2024 Jul 8. doi: 10.1111/his.15275.
    >> Share

  40. ZHANG H, Finkelman BS, Ettel MG, Velez MJ, et al
    HER2 evaluation for clinical decision making in human solid tumours: pearls and pitfalls.
    Histopathology. 2024;85:3-19.
    >> Share

    June 2024
  41. LASHEN AG, Toss M, Miligy I, Rewcastle E, et al
    Nottingham prognostic x (NPx): a risk stratification tool in ER-positive HER2-negative breast cancer: a validation study.
    Histopathology. 2024 Jun 13. doi: 10.1111/his.15234.
    >> Share

  42. MILIGY IM, Awasthi R, Mir Y, Khurana A, et al
    Morphological and molecular changes of oestrogen receptor-positive breast cancer following bridging endocrine therapy: a United Kingdom multicentre study.
    Histopathology. 2024 Jun 7. doi: 10.1111/his.15238.
    >> Share

  43. LAOKULRATH N, Gudi M, Salahuddin SA, Chong APY, et al
    Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges.
    Histopathology. 2024 Jun 6. doi: 10.1111/his.15213.
    >> Share

  44. BOSSUYT V, Provenzano E, Symmans WF, Webster F, et al
    A dedicated structured data set for reporting of invasive carcinoma of the breast in the setting of neoadjuvant therapy: recommendations from the International Collaboration on Cancer Reporting (ICCR).
    Histopathology. 2024;84:1111-1129.
    >> Share

    May 2024
  45. LI J, Dong P, Wang X, Zhang J, et al
    Artificial intelligence enhances whole-slide interpretation of PD-L1 CPS in triple-negative breast cancer: A multi-institutional ring study.
    Histopathology. 2024 May 15. doi: 10.1111/his.15205.
    >> Share

  46. HUANG CY, Chang RF, Lin CY, Hsieh MS, et al
    Deep-learning model to improve histological grading and predict upstaging of atypical ductal hyperplasia / ductal carcinoma in situ on breast biopsy.
    Histopathology. 2024;84:983-1002.
    >> Share

    April 2024
  47. BADR NM, Zaakouk M, Zhang Q, Kearns D, et al
    Concordance between ER, PR, Ki67, and HER2-low expression in breast cancer by MammaTyper RT-qPCR and immunohistochemistry: implications for the practising pathologist.
    Histopathology. 2024 Apr 23. doi: 10.1111/his.15193.
    >> Share

  48. LI JJX, Ni SYB, Tsang JYS, Chan WY, et al
    Neutrophil-lymphocyte ratio reflects tumour-infiltrating lymphocytes and tumour-associated macrophages and independently predicts poor outcome in breast cancers with neoadjuvant chemotherapy.
    Histopathology. 2024;84:810-821.
    >> Share

  49. ALKHAYYAT R, Abbas A, Quinn CM, Rakha EA, et al
    Tumour 63 protein (p63) in breast pathology: biology, immunohistochemistry, diagnostic applications, and pitfalls.
    Histopathology. 2024;84:723-741.
    >> Share

  50. AZAM AS, Tsang YW, Thirlwall J, Kimani PK, et al
    Digital pathology for reporting histopathology samples, including cancer screening samples - definitive evidence from a multisite study.
    Histopathology. 2024;84:847-862.
    >> Share

    March 2024
  51. LY A, Garcia V, Blenman KRM, Ehinger A, et al
    Training pathologists to assess stromal tumour-infiltrating lymphocytes in breast cancer synergises efforts in clinical care and scientific research.
    Histopathology. 2024 Mar 3. doi: 10.1111/his.15140.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016